Asahi Kasei Pharma Begins Phase III Trial in Japan of ART-123 for Preventing Chemotherapy-Induced Peripheral Neuropathy

Asahi Kasei Pharma has started trial drug administration in a Phase III study of ART-123 in Japan (generic name: thrombomodulin alfa; marketed as Recomod...

July 03, 2025 | Thursday | News
MaaT Pharma and Clinigen Sign Exclusive European Licensing Deal for Xervyteg® in Acute Graft-Versus-Host Disease

MaaT Pharma and Clinigen signed exclusive long-term licensing and distribution agreement and commercial supply agreement for Xervyteg® (MaaT013),...

July 03, 2025 | Thursday | News
Modella AI and AstraZeneca Forge Multi-Year Alliance to Power Oncology R&D with Multimodal AI

-Modella AI, a leader in artificial intelligence for life sciences,  announced a multi-year agreement with AstraZeneca. Under the agreement, Modella...

July 03, 2025 | Thursday | News
WeightWatchers Expands Collaboration With Novo Nordisk to Boost Access to FDA-Approved Wegovy® at Special Pricing

WeightWatchers Clinic Members Can Access FDA-Approved Wegovy® for $299 in July, a $200 Savings Offer to Improve Access as WeightWatchers’ Trust...

July 02, 2025 | Wednesday | News
ReproNovo Doses First Participant in Phase 2 Trial of RPN-001, a Novel Oral Therapy for Male Infertility

RPN-001 is a novel orally administered aromatase inhibitor being developed for the treatment of infertility in men with low serum testosterone No FDA-...

July 02, 2025 | Wednesday | News
Addex Therapeutics Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine for Autism and Neuropsychiatric Disorders

Addex Therapeutics , a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for ...

July 01, 2025 | Tuesday | News
Novo Nordisk Partners with WeightWatchers to Expand Access to Wegovy® with New Nationwide Pricing Initiative

Novo Nordisk continues expansion of patient access to Wegovy® (semaglutide) injection 2.4 mg through a new collaboration with WeightWatchers...

June 27, 2025 | Friday | News
Nu Skin Revamps ageLOC® Tru Face® Line with Refillable, Eco-Conscious Packaging

Nu Skin Enterprises Inc. (NYSE: NUS), a global beauty and wellness company, is breathing new life into its iconic ageLOC® Tru Face® line with a r...

June 26, 2025 | Thursday | News
Nutriband and Kindeva Complete Commercial Manufacturing Scale-Up for AVERSA™ Fentanyl, Advancing World’s First Abuse-Deterrent Opioid Patch

Nutriband Inc.  a company engaged in the development of prescription transdermal pharmaceutical products, announced that it has completed commercial...

June 24, 2025 | Tuesday | News
Lilly’s Once-Weekly Efsitora Matches Daily Insulin in Phase 3 Trials, Global Filing Planned by Year-End

Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with...

June 23, 2025 | Monday | Reports
PharmaJet and Immuno Cure Partner to Advance Needle-Free HIV Therapeutic DNA Vaccine with Tropis® ID System

Agreement builds on PharmaJet’s strategy to be the best-in-class delivery system for novel DNA- and RNA-based vaccines and immunotherapies usin...

June 20, 2025 | Friday | News
NeuralCure AI Launches First Diagnostic & Digital Twin OS to Power Patient-Led Healthcare Revolution

NeuralCure AI  announced the official launch of its groundbreaking Diagnostic & Digital Twin Operating System, the first infrastructure platform...

June 20, 2025 | Friday | News
Draig Therapeutics Launches with $140M to Advance Novel Neuropsychiatric Treatments

Clinical-stage company led by world-class team targeting core neurotransmission pathways underlying neuropsychiatric disorders with a rich pipeline of ...

June 19, 2025 | Thursday | News
Incannex and Mind Medicine Australia Launch Joint Venture to Open Psychedelic Therapies Clinic in Melbourne

Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combi...

June 18, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close